AI Article Synopsis
- Glioma is a common and aggressive brain tumor linked to the dysregulation of long non-coding RNAs (lncRNAs), with EIF3J-AS1 being a novel lncRNA that has not been previously studied in glioma.
- Researchers used various assays to investigate the role of EIF3J-AS1 in glioma, finding that it is overexpressed in glioma cells and its knockdown reduces malignant properties of these cells.
- The study reveals that EIF3J-AS1 interacts with miR-1343-3p and ANXA11, forming a regulatory axis that promotes glioma progression, presenting a potential new target for therapeutic intervention.
Article Abstract
Background: Glioma is one prevalent malignant tumor originates from the central nervous system. Dysregulation of long non-coding RNAs (lncRNAs) has been found to be a molecular signature behind the pathology of a variety of cancers, including glioma. EIF3J antisense RNA 1 (EIF3J-AS1) is a novel lncRNA, whose performance in carcinogenesis has been unfolded. Nevertheless, the role of EIF3J-AS1 has never been investigated in glioma.
Methods: qRT-PCR analysis was adopted to evaluate the relative levels of RNAs. In vitro functional assays, including colony formation, EdU, TUNEL and caspase-3/8/9 activity assays were conducted to study the impacts of EIF3J-AS1 on glioma. Dual-luciferase activity assays, RNA pull down assay and RIP assay were performed to elucidate molecular interplay among genes.
Results: EIF3J-AS1 was overexpressed in glioma cell lines. Knockdown of EIF3J-AS1 hampered glioma malignant phenotypes. MiR-1343-3p could bind to EIF3J-AS1. Moreover, miR-1343-3p targeted Annexin A11 (ANXA11) in its 3'UTR region. Mechanistically, EIF3J-AS1 relieved ANXA11 from miR-1343-3p silencing in the EIF3J-AS1/miR-1343-3p/ANXA11 RNA induced silencing complex (RISC), thus eliciting promoting effects on glioma progression. MiR-1343-3p inhibitor and ANXA11 overexpression offset the inhibitory impacts of EIF3J-AS1 silencing on glioma development.
Conclusion: EIF3J-AS1/miR-1343-3p/ANXA11 axis significantly affected biological behaviors in glioma, suggesting new therapeutic target for glioma treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469350 | PMC |
| http://dx.doi.org/10.1186/s12935-020-01487-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancers of the brain and central nervous system: global patterns and trends in incidence.
J Neurooncol
January 2025
Cancer Surveillance Branch, International Agency for Research On Cancer (IARC), 25 Avenue Tony Garnier, CS 90627, 69366 LYON CEDEX 07, Lyon, France.
Background: Global comparisons of the burden and impact of cancers of the brain and central nervous system (CNS) are critical for developing effective control strategies and generating etiological hypotheses to drive future research.
Methods: National incidence estimates were obtained from GLOBOCAN 2022, and recorded incidence data from the Cancer in Five Continents series, both developed and compiled by the International Agency for Research on Cancer. We examined the estimated age-standardized incidence rates in 185 countries, as well as time trends in recorded incidence in 35 countries, quantifying the direction and change in the magnitude of the rates using the estimated average percentage change (EAPC).
Retraction Note: Letter to Editor, "The effects of dabrafenib and/or trametinib treatment in Braf V600mutant glioma: a systematic review and metaanalysis".
Neurosurg Rev
January 2025
Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, 600077, India.
Abietane diterpenoids from and their cytotoxic activities.
Nat Prod Res
January 2025
School of Pharmacy, Jiangxi Provincial Education Department Key Laboratory for the Application of Key Technologies in Drug Screening for Inflammatory Diseases and Phlegm Syndrome, Nanchang Medical College, Nanchang, China.
Two new abietane diterpenoids ( and ) and two known analogs ( and ) were isolated from the whole plants of . Their structures were determined by comprehensive spectroscopic methods (UV, IR, NMR, and HRESIMS). Moreover, all compounds were evaluated for their cytotoxic activities against U251 glioblastoma cells.
View Article and Find Full Text PDFCharacterization of NOD-like receptor-based molecular heterogeneity in glioma and its association with immune micro-environment and metabolism reprogramming.
Front Immunol
January 2025
Department of Neurosurgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Background And Purpose: The characteristics and role of NOD-like receptor (NLR) signaling pathway in high-grade gliomas were still unclear. This study aimed to reveal the association of NLR with clinical heterogeneity of glioblastoma (GBM) patients, and to explore the role of NLR pathway hub genes in the occurrence and development of GBM.
Methods: Transcriptomic data from 496 GBM patients with complete prognostic information were obtained from the TCGA, GEO, and CGGA databases.
Correction to: Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50‑1 Yonsei‑Ro, Seodaemun‑Gu, Seoul, 03722 Republic of Korea.
[This corrects the article DOI: 10.1007/s13139-024-00847-4.].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!